[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643783":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":71,"collaborators":73,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":10,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":10,"studyType":90,"phases":10,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Resonance, Inc.","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Children, Adolescents, and Young Adults With Cancer",null,"Participants include children, adolescents and young adults with a diagnosis of cancer who are receiving routine care at participating hospitals in low- and middle-income countries(LMIC). This study follows patients as part of a single observational cohort and does not assign any experimental treatments. All medical care is provided according to local standard practice. Participants are followed over time to document clinical outcomes, as well as factors related to access to care and the overall treatment experience.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Gabriela Villanueva, MD.","CONTACT","+1-901-205-9518","gabriela.villanueva@resonancehealth.org",[19,36,55],{"facility":20,"status":21,"city":22,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Yeolyan Center for Cancer and Blood Disorders","RECRUITING","Yerevan","Armenia","AM",{"type":26,"coordinates":27},"Point",[28,29],44.5126,40.17765,{"lat":29,"lon":28},[32],{"name":33,"role":15,"phone":34,"phoneExt":10,"email":35},"Anna Avagyan, MD","+010283800","avagyananna2010@gmail.com",{"facility":37,"status":21,"city":38,"state":10,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":46,"contacts":47},"The Children's Cancer Hospital Egypt 57357","Cairo","11441","Egypt","EG",{"type":26,"coordinates":43},[44,45],31.24967,30.06263,{"lat":45,"lon":44},[48,52],{"name":49,"role":15,"phone":50,"phoneExt":10,"email":51},"Iman Sidhom, MD.","(202) 25351500","iman.sidhom@57357.org",{"name":53,"role":15,"phone":50,"phoneExt":10,"email":54},"Alaa El Haddad, MD.","Alaa.Hadad@57357.org",{"facility":56,"status":21,"city":57,"state":10,"zip":10,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Unidad Nacional de Oncología Pediátrica (UNOP)","Guatemala City","Guatemala","GT",{"type":26,"coordinates":61},[62,63],-90.51327,14.64072,{"lat":63,"lon":62},[66],{"name":67,"role":15,"phone":68,"phoneExt":69,"email":70},"Jeanine Alfaro, MD","50223177800","502","jalfaroflowcyt@ayuvi.org.gt",{"type":72,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[74],{"name":75,"class":76},"Servier Affaires Médicales","INDUSTRY","100643783","caya-cancer-prospective-cohort-study-100643783",false,"NCT07632014","CAYA Cancer Prospective Cohort Study","Improving Cancer Outcomes for Children, Adolescents, and Young Adults: A Multicenter Prospective Cohort Study on Treatment Failure and Toxicity in Low- and Middle-Income Countries.","Inclusion Criteria:\n\nSubjects must meet all the following criteria to be included in this study:\n\n1. Age 0 to 21 years at study enrollment.\n2. Diagnosed with cancer and receiving active treatment or undergoing follow-up at the participating sites.\n\n   a. Note: Patients seen solely for consultation or diagnostic evaluations without subsequent treatment and those who have been off treatment for more than 5 years and are seen only for survivorship follow-up are not considered as meeting this criterion.\n3. Willingness to provide informed consent\u002Fassent. For minors incapable of providing assent, or individuals unable to provide consent, consent must be obtained from a legal representative and in accordance with local requirements.\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria must be excluded from this study:\n\n1\\. Any medical or psychological condition that, in the investigator's opinion, might compromise the ability of the patient to provide assent\u002Finformed consent\u002Fassent.","ALL","0 Years","21 Years",{"count":88,"type":89},6000,"ESTIMATED","OBSERVATIONAL","Cancer is a leading cause of illness and death among children, adolescents, and young adults(CAYAs), especially in low- and middle-income countries(LMICs), where access to timely diagnosis and treatment is often limited. As a result, patients in these settings may experience higher rates of treatment complications, interruptions, and poorer outcomes compared with those in high-income countries (HICs).\n\nThis is a prospective, multicenter observational study that will follow children, adolescents, and young adults(CAYAs) with cancer who are receiving routine care at participating hospitals in low - and middle - income countries(LMICs). The study does not involve experimental treatments or changes to standard medical care. Information will be collected from medical records and from questionnaires that address access to care and social factors affecting treatment.\n\nBy describing treatment outcomes and the challenges patients and families face during cancer care, this study aims to provide data that can help inform future efforts to improve access to care and cancer outcomes in resource-limited settings.",[93,94,95,96],"Cancer","Pediatric Cancer","Lymphoblastic Lymphoma (LBL)","Acute Lymphoblastic Leukemia (ALL)",[98,99,100,101,102,103,104,105,106,107,108],"Children, Adolescents, and Young Adults (CAYA)","Low- and middle-income countries (LMIC)","Observational Study","Cancer Outcomes","Treatment-Related Toxicity","Treatment Failure","Treatment Abandonment","Diagnostic Delay","Socioeconomic Factors","High-income countries (HICs)","Central Nervous System(CNS)","2026-06-03",{"date":111,"type":112},"2026-06-08","ACTUAL",{"date":114,"type":112},"2025-11-11",{"date":116,"type":89},"2032-11-11",{"name":5,"class":6},3]